AstraZeneca says a strong 2024 and stacked pipeline spells potential for further growth in 2025 as the company aims to bring in $80bn in revenue by 2030. The company maintains a confident outlook ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

CEOs from large pharma companies AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Merck KGaA, Pfizer and Sanofi were among more than 40 international business leaders who met with Xi in ...

AstraZeneca gains full rights to roxadustat in China, while FibroGen retains US rights and plans an FDA meeting for next development steps. Get special access to three exclusive "Top 10 Stocks ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.

These results were announced at the 2025 ASCO Annual Meeting. DATROWAY was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca. Final Phase 1b TROPION ...

Biggest stock movers Monday: Air mobility stocks, and more IonQ, AstraZeneca, Nvidia and AWS show quantum-accelerated drug development workflow© Provided by Seeking Alpha ...